Table S2.
Demographic and clinical characteristics of patients at baseline
| Characteristics | RT arm (N=30) | RT + erlotinib arm (N=60) |
|---|---|---|
| Sex, male, n (%) | 30 (100.0) | 54 (90.0) |
| Age, median (IQR) | 79.8 (74.6–81.2) | 79.3 (76.7–81.7) |
| Smoking habit, n (%) | ||
| Ex-smokers | 15 (50.0) | 43 (71.7) |
| Smokers | 14 (46.7) | 13 (21.7) |
| Nonsmokers | 1 (3.3) | 4 (6.7) |
| History of interstitial lung disease | 1 (3.3) | 4 (6.7) |
| ECOG-PS, n (%) | ||
| 0 | 0 (0.0) | 3 (5.0) |
| 1 | 18 (60.0) | 38 (63.3) |
| 2 | 12 (40.0) | 19 (31.7) |
| Tumor stage, n (%) | ||
| IA | 4 (13.3) | 7 (11.7) |
| IB | 6 (20.0) | 11 (18.3) |
| IIA | 1 (3.3) | 1 (1.7) |
| IIB | 3 (10.0) | 7 (11.7) |
| IIIA | 4 (13.3) | 10 (16.7) |
| IIIB | 12 (40.0) | 23 (38.3) |
| IV | 0 (0.0) | 1 (1.7) |
| Lung tumor histology, n (%) | ||
| Squamous-cell carcinoma | 14 (46.7) | 28 (46.7) |
| Large-cell carcinoma | 11 (36.7) | 14 (23.3) |
| Adenocarcinoma | 4 (13.3) | 12 (20.0) |
| Others | 1 (3.3) | 6 (10.0) |
| Unresectable tumor, n (%) | 17 (56.7) | 31 (51.7) |
Abbreviations: IQR, interquartile range; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; RT, radiotherapy.